Skip to main content
Fig. 5 | Biology Direct

Fig. 5

From: N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathway

Fig. 5

miR-139-5p is involved in the oncogenic roles of SH3BP5-AS1 in pancreatic cancer. A Venn diagram showing the potential target miRNAs of SH3BP5-AS1 based on the public database ENCORI and the DIANA Tool. B RNA pulldown assay was performed to prove miRNA-139-5p was the most enriched in the precipitate of SH3BP5-AS1 than other miRNA candidates. C Correlation analysis of SH3BP5-AS1 and miRNA-139-5p. D Schematic diagram of the binding sites between SH3BP5-AS1 and miRNA-139-5p. E, F A dual luciferase reporter assay was conducted to determine the relative luciferase activities in pancreatic cancer cells following transfection with the indicated constructs. G miRNA-139-5p was overexpressed following silencing of SH3BP5-AS1 in BxPC-3 and MIA Paca-2 cells. H–J An RIP assay was conducted to evaluate the relative enrichment of SH3BP5-AS1 and miRNA-139-5p in anti-IgG- or anti-AGO2-specific immunoprecipitates in H293T cells. K miRNA-139-5p was downregulated following SH3BP5-AS1 overexpression in PANC-1 cells. L–N An RIP assay was conducted to evaluate the relative enrichment of SH3BP5-AS1 and miRNA-139-5p in anti-IgG- or anti-AGO2-specific immunoprecipitates in MIA Paca-2 cells. O–R An RNA pull-down assay was conducted to detect the interaction among LNCAROD, miR-145-5p, and AGO2 in H293T and MIA Paca-2 cells. Data are shown as the mean ± SD. *P < 0.05; **P < 0.01

Back to article page